drugset / Trial / NCT05497284

To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF

NCT05497284

Phase 2 Terminated 46 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A participant- and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosis

Timeline

Start
2022-11-10
Primary completion
2024-08-26
Completion
2024-09-26

Drugs

EvaluationDrugModalityDoseRoute
Subject LTP001 Unknown Oral
Background Nintedanib Small molecule
Background Pirfenidone Small molecule